Press Releases

Date	Title	PDF Version
Oct 23, 2014	Researchers to Present Data on Soliris® (eculizumab) as a Treatment for Patients with aHUS at ASN 2014 Annual Meeting
Oct 23, 2014	Alexion Reports Third Quarter 2014 Results
Oct 15, 2014	Alexion Submits NDA in Japan for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia
Oct 09, 2014	Alexion Pharmaceuticals to Report Third Quarter 2014 Results on Thursday, October 23, 2014
Oct 09, 2014	Alexion Board of Directors Appoints New Chairman and Creates the New Position of Lead Independent Director
Oct 07, 2014	Alexion Announces the Passing of Max Link, Ph.D., Chairman of the Company's Board of Directors
Sep 17, 2014	Alexion Strengthens and Broadens Its Executive Leadership Team
Sep 14, 2014	Improved Survival Observed in Pediatric Patients with Severe Hypophosphatasia (HPP) Who Were Treated with Investigational Asfotase Alfa for Up to Five Years
Sep 08, 2014	Asfotase Alfa Granted Orphan Drug Designation in Japan
Sep 03, 2014	NICE Recommends Commissioning of Eculizumab (Soliris®) for All Patients with aHUS in England

Search